Sign Up
Stories
AGO Recognition Boosts BluePrint® Impact
Share
4P-Pharma Secures €15 Million Funding
Abeona Therapeutics Grants Inducement Aw...
Advancements in Cancer Treatment and Mar...
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Acrivon Therapeutics' Precision Medicine...
Overview
API
Agendia's BluePrint® assay, included in AGO guidelines, aids in chemotherapy response prediction for breast cancer. The NBRST trial validated its predictive power, supporting personalized treatment decisions by Agendia.
Ask a question
How could the expansion of precision oncology solutions like those offered by Agendia influence future advancements in cancer treatment?
How might the inclusion of BluePrint® in AGO guidelines impact the standard of care for breast cancer patients?
What implications does the NBRST trial's validation of BluePrint® have for the field of oncology and personalized medicine?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage